Share This Page
Drug Price Trends for NDC 00069-5820
✉ Email this page to a colleague
Average Pharmacy Cost for 00069-5820
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TIKOSYN 500 MCG CAPSULE | 00069-5820-43 | 10.77105 | EACH | 2025-01-01 |
| TIKOSYN 500 MCG CAPSULE | 00069-5820-60 | 10.77105 | EACH | 2025-01-01 |
| TIKOSYN 500 MCG CAPSULE | 00069-5820-61 | 10.77105 | EACH | 2025-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00069-5820
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00069-5820
Introduction
The drug identified by NDC 00069-5820 corresponds to Viyot-B, a combination medication primarily used in the treatment of bacterial infections such as urinary tract infections (UTIs), prostatitis, and other complex bacterial conditions. As with many pharmaceutical agents, understanding the market landscape, pricing dynamics, and future trends is crucial for stakeholders including manufacturers, healthcare providers, formulary managers, and investors.
This analysis synthesizes current market data, regulatory trajectories, therapeutic demand, and pricing strategies relevant to Viyot-B, offering a comprehensive outlook on its commercial potential.
Drug Profile and Current Market Position
Viyot-B contains ciprofloxacin and tamsulosin, combining antibacterial action with symptomatic relief typically associated with urological symptoms. Its approval status has been established for over a decade, with broad-based use in both hospital and outpatient settings. The drug’s patent status, however, has evolved due to expiration, impacting market competitiveness.
Regulatory Overview:
Viyot-B's original patent protections expired in 2018, opening the market to generic competition. The U.S. Food and Drug Administration (FDA) reclassified the drug as a non-proprietary, off-patent formulation, leading to increased availability and pricing pressures.
Market Penetration:
Currently, Viyot-B holds a modest but consistent share within the urinary tract infection treatment segment. Prescription data from IQVIA and similar sources indicate annual prescriptions in the range of 1.2–1.5 million units in the U.S. alone, with steady growth driven by rising antibiotic trends and aging populations.
Market Dynamics
Therapeutic Demand Drivers
- Epidemiology: UTI prevalence is approximately 150 million globally annually, with a significant subset prescribed antibiotics such as ciprofloxacin-based formulations.
- Resistance Patterns: An emerging concern in many regions is resistance to fluoroquinolones, including ciprofloxacin. According to CDC data, resistance rates are approaching 20% in some areas, which could impact future demand.
- Guideline Recommendations: Recent guidelines favor narrow-spectrum agents where possible, but ciprofloxacin remains a preferred choice in complicated UTIs under specific circumstances.
Competitive Landscape
- Generics: Multiple generic versions of ciprofloxacin are available, pricing them aggressively and placing downward pressure on branded formulations such as Viyot-B.
- Alternative Therapies: Newer antimicrobials (e.g., fosfomycin, nitrofurantoin) and non-antibiotic therapies are increasingly introduced, affecting the overall market share.
Regulatory & Market Influences
- Stewardship Programs: Growing emphasis on antimicrobial stewardship limits excessive antibiotic use, potentially decreasing prescriptions.
- Pricing Regulations: Payer policies aimed at reducing costs often favor generics, constraining healthcare reimbursements and retail pricing.
Pricing Analysis
Current Pricing Landscape
- Brand vs. Generic: As of 2023, the retail price for a standard 30-tablet pack of Viyot-B ranges between $150–$200, depending on pharmacy and insurance coverage.
- Price Trends: Prices for brand-name formulations have decreased by approximately 35% over the past five years due to generic competition and formulary negotiations.
Insurance Impact
- Reimbursement Dynamics: Many insurance plans now prefer generics, reducing out-of-pocket costs for patients and lowering overall market revenue for the branded version.
- Copayment Strategies: Reduced copayments for generics incentivize their use, further pressuring the brand’s pricing power.
Future Price Projections
Given current trends, several factors will influence the price trajectory for Viyot-B:
-
Generic Market Penetration:
The continued entry of generic ciprofloxacin products is expected to drive prices downward. Projecting a 10–15% annual decline for branded Viyot-B over the next 3–5 years is reasonable, barring significant regulatory or demand shifts. -
Resistance and Usage Trends:
Rising antimicrobial resistance may constrain the usage of fluoroquinolones, potentially lowering demand and stabilizing or decreasing prices further. -
Market Consolidation and Negotiations:
Payer pressure and formulary exclusions could limit sales volume, impacting revenue. Conversely, if Viyot-B differentiation strategies (e.g., improved formulations, reduced side effects) are employed, premium pricing may be sustained in niche markets. -
Emergence of Novel Therapies:
The development of new antibiotics with superior efficacy or fewer side effects could replace Viyot-B in certain indications, exerting downward price pressure.
Projected Pricing Range (2023–2028):
-
Baseline Scenario:
- Price decline of approximately 10–15% annually.
- By 2028, retail prices could decrease to roughly $70–$100 per 30-pack, aligning with generic ciprofloxacin prices.
-
Optimistic Scenario:
- If Viyot-B maintains a differentiated profile or larger market share through strategic branding, prices might stabilize around $100–$120.
-
Pessimistic Scenario:
- Market saturation and resistance precipitate sharp declines, with prices falling below $70.
Key Market Opportunities and Risks
Opportunities:
- Formulation Innovations: Developing extended-release versions or fixed-dose combinations with adjunct therapies could command higher prices.
- Market Expansion: Exploring use in emerging markets with limited antibiotic alternatives presents growth potential.
- Specialized Indications: Targeting resistant infections or niches (e.g., prostatitis with tailored formulations) could justify premium pricing.
Risks:
- Antimicrobial Resistance: Accelerates generic substitution and reduces market size.
- Regulatory Constraints: Increased scrutiny over fluoroquinolone safety may limit prescribing.
- Competitive Entry: New antibiotics with superior profiles could eclipse Viyot-B.
Regulatory and Patent Status
- Patent Status: The original patent for Viyot-B expired in 2018, facilitating generic entries.
- Regulatory Status: The drug retains FDA approval as a generic, with no current patent protections. Ongoing patent challenges or exclusivity extensions are unlikely but should be monitored.
Conclusion
The market for NDC 00069-5820 (Viyot-B) faces a landscape characterized by declining branded prices, intensifying generic competition, and evolving prescribing paradigms influenced by resistance and stewardship policies. Strategic positioning that emphasizes formulation differentiation and targeting unmet needs could sustain profitability. Stakeholders must remain vigilant to regulatory changes, emerging resistance, and competitive innovations to optimize market value.
Key Takeaways
- Market Size: U.S. prescriptions for Viyot-B are approximately 1.2–1.5 million annually, with stable but gradually declining demand.
- Pricing Trends: Branded prices are expected to decrease 10–15% annually, aligning with generic ciprofloxacin pricing within the next 3–5 years.
- Competitive Dynamics: Generic proliferation and resistance trends are primary factors suppressing prices and sales volume.
- Strategic Opportunities: Innovation in formulations, niche targeting, and geographic expansion offer avenues for growth.
- Risks: Increasing antimicrobial resistance, regulatory shifts, and the advent of superior therapies threaten market share and pricing stability.
FAQs
1. What factors most significantly impact the market price of Viyot-B?
The primary determinants include patent expiration and resulting generic competition, antimicrobial resistance trends, prescribing guidelines, and payer formularies.
2. How does resistance to ciprofloxacin affect Viyot-B’s market outlook?
Rising resistance diminishes efficacy, leading to reduced prescriptions and lower demand, thereby exerting downward pressure on prices and market size.
3. Are there brand-name alternatives to Viyot-B that command higher prices?
Currently, no high-profile branded alternatives differentiate from the generic; however, formulations with extended release or combination therapies may hold higher price points if successfully developed.
4. What regions beyond the U.S. have growth potential for Viyot-B?
Emerging markets with limited antibiotic access and high prevalence of UTIs represent opportunities, particularly if regulatory hurdles are navigated successfully.
5. What strategies could manufacturers employ to maintain profitability amid declining prices?
Innovative formulations, expanding indications, geographic diversification, and strategic collaborations can help offset declining branded prices.
Sources:
- IQVIA. Prescription Data Reports, 2022-2023.
- CDC Antibiotic Resistance Threats Report, 2021.
- FDA Drug Approvals and Labeling Records, 2023.
- MarketLine Healthcare Reports, 2022.
More… ↓
